image
Healthcare - Medical - Devices - NYSE - US
$ 26.65
-1.26 %
$ 1.12 B
Market Cap
-888.33
P/E
1. INTRINSIC VALUE

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system.[ Read More ]

The intrinsic value of one AORT stock under the base case scenario is HIDDEN Compared to the current market price of 26.6 USD, Artivion, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AORT

image
FINANCIALS
354 M REVENUE
12.82%
5.74 M OPERATING INCOME
77.22%
-30.7 M NET INCOME
-59.91%
18.8 M OPERATING CASH FLOW
465.32%
-502 K INVESTING CASH FLOW
95.31%
865 K FINANCING CASH FLOW
152.78%
95.8 M REVENUE
-2.29%
4.39 M OPERATING INCOME
-46.89%
12.6 M NET INCOME
697.17%
14.3 M OPERATING CASH FLOW
132.93%
-29.5 M INVESTING CASH FLOW
-1072.58%
10.5 M FINANCING CASH FLOW
5909.39%
Balance Sheet Decomposition Artivion, Inc.
image
Current Assets 231 M
Cash & Short-Term Investments 58.9 M
Receivables 74.1 M
Other Current Assets 97.8 M
Non-Current Assets 562 M
Long-Term Investments 0
PP&E 82.2 M
Other Non-Current Assets 479 M
Current Liabilities 57.9 M
Accounts Payable 13.3 M
Short-Term Debt 5.43 M
Other Current Liabilities 39.1 M
Non-Current Liabilities 453 M
Long-Term Debt 353 M
Other Non-Current Liabilities 99.8 M
EFFICIENCY
Earnings Waterfall Artivion, Inc.
image
Revenue 354 M
Cost Of Revenue 125 M
Gross Profit 229 M
Operating Expenses 223 M
Operating Income 5.74 M
Other Expenses 36.4 M
Net Income -30.7 M
RATIOS
64.74% GROSS MARGIN
64.74%
1.62% OPERATING MARGIN
1.62%
-8.67% NET MARGIN
-8.67%
-10.89% ROE
-10.89%
-3.87% ROA
-3.87%
1.39% ROIC
1.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Artivion, Inc.
image
Net Income -30.7 M
Depreciation & Amortization 23.1 M
Capital Expenditures -7.43 M
Stock-Based Compensation 14.4 M
Change in Working Capital -16.2 M
Others 30.1 M
Free Cash Flow 11.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Artivion, Inc.
image
Wall Street analysts predict an average 1-year price target for AORT of $30.6 , with forecasts ranging from a low of $30 to a high of $33 .
AORT Lowest Price Target Wall Street Target
30 USD 12.57%
AORT Average Price Target Wall Street Target
30.6 USD 14.82%
AORT Highest Price Target Wall Street Target
33 USD 23.83%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.03 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Artivion, Inc.
image
Sold
0-3 MONTHS
410 K USD 2
3-6 MONTHS
542 K USD 3
6-9 MONTHS
5.12 M USD 9
9-12 MONTHS
936 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 01, 2024
Sell 325 K USD
Horton Amy
VP, Chief Accounting Officer
- 12430
26.1798 USD
2 months ago
Aug 26, 2024
Sell 84.1 K USD
Holloway Jean F
SVP, General Counsel
- 3167
26.5538 USD
3 months ago
Aug 16, 2024
Sell 174 K USD
Getz Matthew A
VP, Human Resources
- 6858
25.3115 USD
3 months ago
Aug 16, 2024
Sell 64.8 K USD
Getz Matthew A
VP, Human Resources
- 2562
25.3115 USD
3 months ago
Aug 15, 2024
Sell 61.4 K USD
Holloway Jean F
SVP, General Counsel
- 2383
25.7629 USD
3 months ago
Aug 13, 2024
Sell 243 K USD
SEMEDO ANTHONY B.
Director
- 9709
24.99 USD
6 months ago
May 10, 2024
Sell 29.3 K USD
Holloway Jean F
SVP, General Counsel
- 1250
23.4201 USD
6 months ago
May 09, 2024
Sell 23.3 K USD
Holloway Jean F
SVP, General Counsel
- 979
23.785 USD
7 months ago
Mar 20, 2024
Sell 44.5 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 2183
20.39 USD
8 months ago
Mar 15, 2024
Sell 29.2 K USD
GREEN ANDREW M
VP Regulatory
- 1462
20 USD
8 months ago
Mar 14, 2024
Sell 79.9 K USD
GREEN ANDREW M
VP Regulatory
- 3994
20 USD
8 months ago
Mar 12, 2024
Sell 99.7 K USD
Getz Matthew A
VP, Human Resources
- 5000
19.9439 USD
8 months ago
Feb 26, 2024
Sell 19.6 K USD
Horton Amy
VP, Chief Accounting Officer
- 966
20.2711 USD
8 months ago
Feb 26, 2024
Sell 23.7 K USD
Horton Amy
VP, Chief Accounting Officer
- 1168
20.2711 USD
8 months ago
Feb 26, 2024
Sell 29 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1431
20.2711 USD
8 months ago
Feb 26, 2024
Sell 31.9 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1576
20.2711 USD
8 months ago
Feb 26, 2024
Sell 22.6 K USD
Maney Rochelle L.
VP, Quality
- 1114
20.2711 USD
8 months ago
Feb 26, 2024
Sell 23.7 K USD
Maney Rochelle L.
VP, Quality
- 1168
20.2711 USD
8 months ago
Feb 26, 2024
Sell 31.3 K USD
Holloway Jean F
SVP, General Counsel
- 1543
20.2711 USD
8 months ago
Feb 26, 2024
Sell 26.3 K USD
Holloway Jean F
SVP, General Counsel
- 1295
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24.3 K USD
GREEN ANDREW M
VP Regulatory
- 1199
20.2711 USD
8 months ago
Feb 26, 2024
Sell 23.7 K USD
GREEN ANDREW M
VP Regulatory
- 1168
20.2711 USD
8 months ago
Feb 26, 2024
Sell 38 K USD
Davis John E
Chief Commercial Officer
- 1875
20.2711 USD
8 months ago
Feb 26, 2024
Sell 32.1 K USD
Davis John E
Chief Commercial Officer
- 1586
20.2711 USD
8 months ago
Feb 27, 2024
Sell 9.22 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 465
19.8344 USD
8 months ago
Feb 27, 2024
Sell 7.34 K USD
Maney Rochelle L.
VP, Quality
- 370
19.8345 USD
8 months ago
Feb 27, 2024
Sell 8.35 K USD
GREEN ANDREW M
VP Regulatory
- 421
19.8344 USD
8 months ago
Feb 27, 2024
Sell 6.45 K USD
Horton Amy
VP, Chief Accounting Officer
- 325
19.8344 USD
8 months ago
Feb 27, 2024
Sell 11.6 K USD
Davis John E
Chief Commercial Officer
- 584
19.8344 USD
8 months ago
Feb 26, 2024
Sell 263 K USD
Mackin James P
President & CEO
- 12968
20.2711 USD
8 months ago
Feb 26, 2024
Sell 362 K USD
Mackin James P
President & CEO
- 17868
20.2711 USD
8 months ago
Feb 27, 2024
Sell 9.62 K USD
Holloway Jean F
SVP, General Counsel
- 485
19.8344 USD
8 months ago
Mar 05, 2024
Sell 21.6 K USD
Horton Amy
VP, Chief Accounting Officer
- 1152
18.7223 USD
8 months ago
Mar 01, 2024
Sell 28.2 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1506
18.7221 USD
8 months ago
Feb 26, 2024
Sell 22.5 K USD
Getz Matthew A
VP, Human Resources
- 1112
20.2711 USD
8 months ago
Feb 26, 2024
Sell 23.7 K USD
Getz Matthew A
VP, Human Resources
- 1168
20.2711 USD
8 months ago
Feb 27, 2024
Sell 6.45 K USD
Getz Matthew A
VP, Human Resources
- 325
19.8344 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
Maney Rochelle L.
VP, Quality
- 1157
18.7224 USD
8 months ago
Feb 27, 2024
Sell 95.9 K USD
Mackin James P
President & CEO
- 4837
19.8344 USD
8 months ago
Mar 05, 2024
Sell 44.6 K USD
Holloway Jean F
SVP, General Counsel
- 2380
18.7222 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
GREEN ANDREW M
VP Regulatory
- 1160
18.7221 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
Getz Matthew A
VP, Human Resources
- 1157
18.722 USD
8 months ago
Mar 05, 2024
Sell 37.9 K USD
Davis John E
Chief Commercial Officer
- 2022
18.7222 USD
8 months ago
Mar 05, 2024
Sell 262 K USD
Mackin James P
President & CEO
- 13996
18.7223 USD
8 months ago
Mar 05, 2024
Sell 262 K USD
Mackin James P
President & CEO
- 13996
18.7223 USD
8 months ago
Mar 05, 2024
Sell 44.6 K USD
Holloway Jean F
SVP, General Counsel
- 2380
18.7222 USD
8 months ago
Mar 05, 2024
Sell 37.9 K USD
Davis John E
Chief Commercial Officer
- 2022
18.7222 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
Getz Matthew A
VP, Human Resources
- 1157
18.722 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
Maney Rochelle L.
VP, Quality
- 1157
18.7224 USD
8 months ago
Mar 05, 2024
Sell 21.7 K USD
GREEN ANDREW M
VP Regulatory
- 1160
18.7221 USD
8 months ago
Mar 05, 2024
Sell 28.2 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1506
18.7221 USD
8 months ago
Mar 05, 2024
Sell 21.6 K USD
Horton Amy
VP, Chief Accounting Officer
- 1152
18.7223 USD
8 months ago
Feb 27, 2024
Sell 6.72 K USD
Tyrs Florian
VP, Global Operations
- 339
19.8344 USD
8 months ago
Feb 27, 2024
Sell 6.45 K USD
Horton Amy
VP, Chief Accounting Officer
- 325
19.8344 USD
8 months ago
Feb 27, 2024
Sell 95.9 K USD
Mackin James P
President & CEO
- 4837
19.8345 USD
8 months ago
Feb 27, 2024
Sell 9.62 K USD
Holloway Jean F
SVP, General Counsel
- 485
19.8344 USD
8 months ago
Feb 27, 2024
Sell 11.6 K USD
Davis John E
Chief Commercial Officer
- 584
19.8344 USD
8 months ago
Feb 27, 2024
Sell 7.34 K USD
Maney Rochelle L.
VP, Quality
- 370
19.8345 USD
8 months ago
Feb 27, 2024
Sell 6.45 K USD
Getz Matthew A
VP, Human Resources
- 325
19.8344 USD
8 months ago
Feb 27, 2024
Sell 8.35 K USD
GREEN ANDREW M
VP Regulatory
- 421
19.8344 USD
8 months ago
Feb 27, 2024
Sell 9.22 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 465
19.8344 USD
8 months ago
Feb 26, 2024
Sell 19.9 K USD
Horton Amy
VP, Chief Accounting Officer
- 980
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24 K USD
Horton Amy
VP, Chief Accounting Officer
- 1186
20.2711 USD
8 months ago
Feb 26, 2024
Sell 267 K USD
Mackin James P
President & CEO
- 13168
20.2711 USD
8 months ago
Feb 26, 2024
Sell 368 K USD
Mackin James P
President & CEO
- 18144
20.2711 USD
8 months ago
Feb 26, 2024
Sell 31.7 K USD
Holloway Jean F
SVP, General Counsel
- 1566
20.2711 USD
8 months ago
Feb 26, 2024
Sell 26.6 K USD
Holloway Jean F
SVP, General Counsel
- 1314
20.2711 USD
8 months ago
Feb 26, 2024
Sell 22.9 K USD
Maney Rochelle L.
VP, Quality
- 1130
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24 K USD
Maney Rochelle L.
VP, Quality
- 1185
20.2711 USD
8 months ago
Feb 26, 2024
Sell 38.6 K USD
Davis John E
Chief Commercial Officer
- 1904
20.2711 USD
8 months ago
Feb 26, 2024
Sell 32.6 K USD
Davis John E
Chief Commercial Officer
- 1610
20.2711 USD
8 months ago
Feb 26, 2024
Sell 22.9 K USD
Getz Matthew A
VP, Human Resources
- 1128
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24 K USD
Getz Matthew A
VP, Human Resources
- 1185
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24.7 K USD
GREEN ANDREW M
VP Regulatory
- 1218
20.2711 USD
8 months ago
Feb 26, 2024
Sell 24 K USD
GREEN ANDREW M
VP Regulatory
- 1185
20.2711 USD
8 months ago
Feb 26, 2024
Sell 29.4 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1448
20.2711 USD
8 months ago
Feb 26, 2024
Sell 32.4 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1600
20.2711 USD
8 months ago
Feb 26, 2024
Sell 18.1 K USD
Tyrs Florian
VP, Global Operations
- 893
20.2722 USD
8 months ago
Feb 20, 2024
Sell 35.3 K USD
Holloway Jean F
SVP, General Counsel
- 1871
18.865 USD
8 months ago
Feb 20, 2024
Sell 8.75 K USD
Holloway Jean F
SVP, General Counsel
- 464
18.865 USD
8 months ago
Feb 20, 2024
Sell 22.5 K USD
Holloway Jean F
SVP, General Counsel
- 1192
18.865 USD
8 months ago
Feb 20, 2024
Sell 25.1 K USD
Horton Amy
VP, Chief Accounting Officer
- 1329
18.865 USD
8 months ago
Feb 20, 2024
Sell 6.9 K USD
Horton Amy
VP, Chief Accounting Officer
- 366
18.865 USD
8 months ago
Feb 20, 2024
Sell 38.9 K USD
Davis John E
Chief Commercial Officer
- 2060
18.865 USD
8 months ago
Feb 20, 2024
Sell 9.36 K USD
Davis John E
Chief Commercial Officer
- 496
18.865 USD
8 months ago
Feb 20, 2024
Sell 7.68 K USD
Maney Rochelle L.
VP, Quality
- 407
18.865 USD
8 months ago
Feb 20, 2024
Sell 25.1 K USD
Getz Matthew A
VP, Human Resources
- 1329
18.865 USD
8 months ago
Feb 20, 2024
Sell 6.9 K USD
Getz Matthew A
VP, Human Resources
- 366
18.865 USD
8 months ago
Feb 20, 2024
Sell 4.7 K USD
Tyrs Florian
VP, Global Operations
- 249
18.865 USD
8 months ago
Feb 20, 2024
Sell 1.12 M USD
Mackin James P
President & CEO
- 59225
18.8521 USD
8 months ago
Feb 20, 2024
Sell 190 K USD
Mackin James P
President & CEO
- 10088
18.865 USD
8 months ago
Feb 20, 2024
Sell 52 K USD
Mackin James P
President & CEO
- 2756
18.865 USD
10 months ago
Jan 02, 2024
Sell 382 K USD
Holloway Jean F
SVP, General Counsel
- 21229
18 USD
10 months ago
Jan 02, 2024
Sell 244 K USD
Davis John E
Senior VP, Global Sales
- 13562
18 USD
11 months ago
Dec 15, 2023
Sell 274 K USD
Horton Amy
VP, Chief Accounting Officer
- 14397
19 USD
11 months ago
Nov 27, 2023
Sell 36.4 K USD
Horton Amy
VP, Chief Accounting Officer
- 2101
17.34 USD
1 year ago
Jun 06, 2023
Sell 242 K USD
Maier Dennis B
SVP, Operations
- 15876
15.266 USD
1 year ago
Jun 06, 2023
Sell 5.8 K USD
Maier Dennis B
SVP, Operations
- 378
15.3426 USD
1 year ago
Jun 07, 2023
Sell 100 K USD
Getz Matthew A
VP, Human Resources
- 6329
15.8766 USD
1 year ago
Mar 02, 2023
Sell 15 K USD
Maier Dennis B
SVP, Operations
- 1121
13.4118 USD
1 year ago
Mar 02, 2023
Sell 11 K USD
Maney Rochelle L.
VP, Quality
- 821
13.4118 USD
1 year ago
Mar 02, 2023
Sell 9.42 K USD
Horton Amy
VP, Chief Accounting Officer
- 702
13.4118 USD
1 year ago
Mar 02, 2023
Sell 9.42 K USD
Getz Matthew A
VP, Human Resources
- 702
13.4118 USD
1 year ago
Mar 02, 2023
Sell 134 K USD
Mackin James P
President & CEO
- 9990
13.4118 USD
1 year ago
Mar 02, 2023
Sell 11.1 K USD
GREEN ANDREW M
VP Regulatory
- 825
13.4118 USD
1 year ago
Mar 02, 2023
Sell 18.8 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 1401
13.4118 USD
1 year ago
Mar 02, 2023
Sell 12.2 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 907
13.4118 USD
1 year ago
Mar 02, 2023
Sell 15 K USD
Davis John E
Senior VP, Global Sales
- 1121
13.4118 USD
1 year ago
Mar 02, 2023
Sell 12.2 K USD
Holloway Jean F
SVP, General Counsel
- 907
13.4118 USD
1 year ago
Feb 27, 2023
Sell 8.69 K USD
Horton Amy
VP, Chief Accounting Officer
- 672
12.938 USD
1 year ago
Feb 27, 2023
Sell 9.66 K USD
Horton Amy
VP, Chief Accounting Officer
- 747
12.938 USD
1 year ago
Feb 27, 2023
Sell 20.7 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 1602
12.938 USD
1 year ago
Feb 27, 2023
Sell 19.3 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 1492
12.938 USD
1 year ago
Feb 27, 2023
Sell 12.9 K USD
Holloway Jean F
SVP, General Counsel
- 994
12.938 USD
1 year ago
Feb 27, 2023
Sell 12.5 K USD
Holloway Jean F
SVP, General Counsel
- 966
12.938 USD
1 year ago
Feb 27, 2023
Sell 15.6 K USD
Davis John E
Senior VP, Global Sales
- 1208
12.938 USD
1 year ago
Feb 27, 2023
Sell 15.3 K USD
Davis John E
Senior VP, Global Sales
- 1185
12.938 USD
1 year ago
Feb 28, 2023
Sell 5.37 K USD
Maney Rochelle L.
VP, Quality
- 406
13.236 USD
1 year ago
Feb 27, 2023
Sell 11.4 K USD
Maney Rochelle L.
VP, Quality
- 878
12.938 USD
1 year ago
Feb 27, 2023
Sell 11.2 K USD
GREEN ANDREW M
VP Regulatory
- 869
12.938 USD
1 year ago
Feb 27, 2023
Sell 11.4 K USD
GREEN ANDREW M
VP Regulatory
- 878
12.938 USD
1 year ago
Feb 27, 2023
Sell 129 K USD
Mackin James P
President & CEO
- 9985
12.938 USD
1 year ago
Feb 27, 2023
Sell 164 K USD
Mackin James P
President & CEO
- 12645
12.938 USD
1 year ago
Feb 27, 2023
Sell 12.7 K USD
Maier Dennis B
SVP, Operations
- 982
12.938 USD
1 year ago
Feb 27, 2023
Sell 17.4 K USD
Maier Dennis B
SVP, Operations
- 1348
12.938 USD
1 year ago
Feb 27, 2023
Sell 15 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1161
12.938 USD
1 year ago
Feb 27, 2023
Sell 15.2 K USD
Stanton Marshall S.
SVP, Clinical & MD Affair
- 1176
12.938 USD
1 year ago
Feb 27, 2023
Sell 9.34 K USD
Getz Matthew A
VP, Human Resources
- 722
12.938 USD
1 year ago
Feb 27, 2023
Sell 11.4 K USD
Getz Matthew A
VP, Human Resources
- 878
12.938 USD
1 year ago
Feb 17, 2023
Sell 211 K USD
Horton Amy
VP, Chief Accounting Officer
- 15000
14.0774 USD
1 year ago
Feb 17, 2023
Sell 42.4 K USD
Horton Amy
VP, Chief Accounting Officer
- 3000
14.1305 USD
1 year ago
Feb 14, 2023
Sell 422 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 31900
13.2249 USD
1 year ago
Feb 14, 2023
Sell 747 K USD
Mackin James P
President & CEO
- 56500
13.2249 USD
1 year ago
Dec 14, 2022
Sell 43.8 K USD
Horton Amy
VP, Chief Accounting Officer
- 3226
13.5718 USD
2 years ago
Aug 16, 2022
Sell 164 K USD
Maney Rochelle L.
VP, Quality
- 7161
22.959 USD
2 years ago
Aug 09, 2022
Sell 22.1 K USD
Maier Dennis B
SVP, Operations
- 1025
21.6079 USD
2 years ago
Feb 10, 2022
Sell 190 K USD
Mackin James P
President & CEO
- 10639
17.8586 USD
2 years ago
Feb 09, 2022
Sell 193 K USD
Mackin James P
President & CEO
- 10638
18.1415 USD
2 years ago
Feb 09, 2022
Sell 193 K USD
Mackin James P
President & CEO
- 10638
18.1415 USD
2 years ago
Feb 10, 2022
Sell 190 K USD
Mackin James P
President & CEO
- 10639
17.8586 USD
2 years ago
Feb 08, 2022
Sell 189 K USD
Mackin James P
President & CEO
- 10638
17.745 USD
2 years ago
Feb 07, 2022
Sell 184 K USD
Mackin James P
President & CEO
- 10638
17.3014 USD
2 years ago
Dec 08, 2021
Sell 46.4 K USD
Horton Amy
VP, Chief Accounting Officer
- 2500
18.5688 USD
2 years ago
Nov 29, 2021
Bought 10.4 K USD
Davis John E
Senior VP, Global Sales
+ 600
17.33 USD
2 years ago
Nov 29, 2021
Bought 260 K USD
SEMEDO ANTHONY B.
Director
+ 15000
17.36 USD
3 years ago
Aug 31, 2021
Sell 17.6 K USD
Holloway Jean F
SVP, General Counsel
- 663
26.4946 USD
3 years ago
Aug 25, 2021
Sell 145 K USD
McCall Ronald D
Director
- 5667
25.6336 USD
3 years ago
Aug 23, 2021
Sell 69.6 K USD
Maier Dennis B
Vice President, Operations
- 2715
25.6402 USD
3 years ago
May 25, 2021
Sell 160 K USD
Davis John E
Senior VP, Global Sales
- 5402
29.6695 USD
3 years ago
May 25, 2021
Sell 26.1 K USD
Davis John E
Senior VP, Global Sales
- 880
29.6989 USD
3 years ago
May 25, 2021
Sell 191 K USD
Davis John E
Senior VP, Global Sales
- 6457
29.6531 USD
3 years ago
May 25, 2021
Sell 171 K USD
McCall Ronald D
Director
- 5783
29.5501 USD
3 years ago
May 06, 2021
Sell 172 K USD
Horton Amy
VP, Chief Accounting Officer
- 5731
30 USD
3 years ago
May 06, 2021
Sell 202 K USD
Holloway Jean F
SVP, General Counsel
- 6618
30.5 USD
3 years ago
May 05, 2021
Sell 817 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 27242
30 USD
3 years ago
May 05, 2021
Sell 156 K USD
Horton Amy
VP, Chief Accounting Officer
- 5186
30 USD
3 years ago
May 05, 2021
Sell 195 K USD
Holloway Jean F
SVP, General Counsel
- 6618
29.5 USD
3 years ago
Apr 30, 2021
Sell 92.8 K USD
Maier Dennis B
Vice President, Operations
- 3314
28 USD
3 years ago
Apr 30, 2021
Sell 825 K USD
Mackin James P
President & CEO
- 29469
28 USD
3 years ago
Apr 30, 2021
Sell 204 K USD
LEE DAVID ASHLEY
Executive VP, COO & CFO
- 6800
30 USD
3 years ago
Apr 30, 2021
Sell 81 K USD
Horton Amy
VP, Chief Accounting Officer
- 2700
30 USD
3 years ago
Mar 10, 2021
Sell 42.8 K USD
Holloway Jean F
SVP, General Counsel
- 1693
25.279 USD
3 years ago
Mar 01, 2021
Sell 348 K USD
Horton Amy
VP, Chief Accounting Officer
- 13619
25.5313 USD
3 years ago
Feb 17, 2021
Sell 164 K USD
Maier Dennis B
Vice President, Operations
- 6630
24.7335 USD
3 years ago
Feb 17, 2021
Sell 14 K USD
Maier Dennis B
Vice President, Operations
- 567
24.6436 USD
3 years ago
Dec 15, 2020
Sell 179 K USD
Capps Scott B
VP, Clinical Research
- 8366
21.3427 USD
3 years ago
Dec 14, 2020
Sell 101 K USD
McCall Ronald D
Director
- 4638
21.7914 USD
7. News
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Daniel Stauder - JMP Securities Suraj Kalia - Oppenheimer Nelson Cox - Lake Street Capital Mike Matson - Needham & Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Third Quarter 2024 Financial Conference Call. At this time, all participants are in listen only mode. seekingalpha.com - 1 week ago
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. zacks.com - 1 week ago
Artivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China. Commercialization expected in the second half of 2025. prnewswire.com - 1 week ago
Artivion to Participate in Upcoming Investor Conferences ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace. prnewswire.com - 1 week ago
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com - 3 weeks ago
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting 5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfusion Resolution in 90% of Affected Subjects Post-AMDS Implantation 1-Year Data from the NEOS Study Indicate E-vita Open Neo is Safe and Effective in the Treatment of Aortic Arch Pathologies with Low Combined Major Adverse Events Rate ATLANTA , Oct. 10, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal. The presentation regarding the AMDS DARTS trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following AMDS implantation. prnewswire.com - 1 month ago
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call. seekingalpha.com - 3 months ago
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago. zacks.com - 3 months ago
Artivion Reports Second Quarter 2024 Financial Results Second Quarter Highlights:  Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basis Net loss was ($2.1) million or ($0.05) per fully diluted share and non-GAAP net income was $2.9 million or $0.07 per fully diluted share in the second quarter of 2024 Adjusted EBITDA increased 35% to $18.6 million in the second quarter of 2024 compared to $13.8 million in the second quarter of 2023 Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint Raised FY24 adjusted EBITDA guidance to 28% to 34% year-over-year growth, an increase of 1% at the midpoint ATLANTA , Aug. 8, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024. "In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. prnewswire.com - 3 months ago
Artivion to Participate in Upcoming Investor Conferences ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel. prnewswire.com - 3 months ago
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com - 3 months ago
3 Earnings All-Stars With More Room to Run Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation. investorplace.com - 4 months ago
8. Profile Summary

Artivion, Inc. AORT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.12 B
Dividend Yield 0.00%
Description Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Contact 1655 Roberts Boulevard N.W., Kennesaw, GA, 30144 https://artivion.com
IPO Date Feb. 12, 1993
Employees 1500
Officers Mr. John E. Davis Senior Vice President & Chief Commercial Officer Mr. James Patrick Mackin Chairman, President & Chief Executive Officer Mr. Matthew A. Getz Vice President of Human Resources & Chief Human Resources Officer Ms. Jean F. Holloway Esq. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Amy D. Horton CPA Vice President & Chief Accounting Officer Dr. Marshall S. Stanton M.D. Senior Vice President of Clinical Research & Chief Medical Officer Dr. Robert C. Thomson Vice President of Research & Development Mr. Florian Tyrs Vice President of Global Operations Mr. Lance A. Berry CPA Executive Vice President of Finance, Chief Operating Officer & Chief Financial Officer